TABLE 2.
Efficacy outcomes
| Outcome |
Result Median (95% CI) |
|---|---|
| First‐line GEM‐NabP Efficacy | |
| Overall survival | 7.5 mo (6.51‐10.33 mo) |
| Overall survival ‐ stratified by ECOG performance status | |
| 0 | 12.7 mo (8.49‐18.49 mo) |
| 1 | 9.6 mo (6.48‐12.04 mo) |
| 2 | 5.3 mo (4.41‐10.2 mo) |
| 3 | 1.6 mo (NA) |
| P value = <.0001 | |
| Progression‐free survival | 2.8 mo (2.3‐3.68 mo) |
| Progression‐free survival stratified by ECOG performance status | |
| 0 | 5.3 mo (2.73‐9.11 mo) |
| 1 | 2.8 mo (2.24‐4.34 mo) |
| 2 | 1.8 mo (1.41‐3.59 mo) |
| 3 | 1.4 mo (NA) |
| P value = .0072 | |
| Radiographic scan result | |
| Disease control | 68 (48.6%) |
| Progression/ Toxicity | 72 (51.4%) |
| Second‐Line GEM‐NabP Efficacy | |
| Overall Survival | 7.6 mo (6.12‐8.26 mo) |
| Overall Survival ‐ stratified by ECOG performance status | |
| 0 | 8 mo (6.22‐12.99 mo) |
| 1 | 7.3 mo (5.33‐9.14 mo) |
| 2 | 6.1 mo (4.61 mo ‐ NA) |
| P value = .581 | |
| Progression‐free survival | 2.5 mo (2.14‐3.85 mo) |
| Progression‐free survival stratified by ECOG performance status | |
| 0 | 3.5 mo (2.07‐7.24 mo) |
| 1 | 2.4 mo (2.07‐2.99 mo) |
| 2 | 2.6 mo (1.74 mo ‐ NA) |
| P value = .362 | |
| Radiographic scan result | |
| Disease control | 38 (40%) |
| Progression/Toxicity | 57 (60%) |
Abbreviations: CI, confidence interval; ECOG, Eastern cooperative oncology group; NA, not estimable.